Wuyou Jump Completes Nearly RMB 100 Million Series A Funding Round

Recently, WYTD MEDICAL TECHNOLOGY (SHENZHEN) CO., LTD. (referred to as: WYTD) announced the completion of nearly RMB 100 million in Series A financing. This round of financing was led by Taiping Medical Health Fund, with Yangtze River Capital participating.

The funds from this round of financing will be used to accelerate the industrialization and commercialization of a complete solution for Patent Foramen Ovale (PFO), enhance the innovative product portfolio in the field of structural heart disease, and fulfill the mission of "maximizing patients' quality of life and perfecting the last line of defense for life." With the successful completion of this round of financing, WYTD has formed a diversified shareholder lineup, including insurance capital, securities firms, industry listed companies, and venture capital institutions.

WYTD was founded in 2021 as a national high-tech enterprise focusing on the diagnosis and treatment of pan-vascular diseases. The current product line mainly revolves around PFO, aiming to provide a complete set of comprehensive PFO diagnosis and treatment solutions. The company always upholds the core values of "innovation, collaboration, hard work, and win-win," adhering to the noble mission of "maximizing patients' quality of life and perfecting the last line of defense for life." It is committed to providing innovative medical device solutions for patients, aspiring to become a leader in innovative cardiac medical devices within ten years.